Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- CTI BioPharma
- Study ID
- NCT00060671
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Lymphoma, Follicular
- Lymphoma, Low-Grade
- Lymphoma, Mixed-Cell, Follicular
- Lymphoma, Small Cleaved-Cell, Follicular
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — DRUG
- Pixantrone (BBR 2778) — DRUG
Study Details
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
Key Dates
- Start date
- Jan 31, 2005
- Status verified
- May 2013
- Primary completion
- Jan 31, 2006
- Completion
- Jan 31, 2006
Study Design
- Enrollment
- 800 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Compare the time to tumor progression (TTP) of the combination of BBR 2778 (pixantrone) + rituximab with that of rituximab alone [ Time Frame: For 5 years post treatment ]
Locations (38)
Find similar trials in Tucson, AZ
By research site
Related Studies
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )PHASE1 · Not Yet Recruiting · Eli Lilly and Company · Duarte, California